Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 522 clinical trials
An Open-Label Phase 3 Study to Examine the Long-Term Safety Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

hoehn and yahr scale
mini-mental state examination
carbidopa
dopa
levodopa
  • 146 views
  • 02 Apr, 2020
  • 1 location
M19-304: A Randomized, Double-Blind, Placebo Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ABBV-0805 in Patients with Parkinson's Disease

The purpose of this study is to learn about the safety, tolerability, pharmacokinetics (the amount of drug absorbed into the blood stream), and immunogenicity (the ability of the body to generate an immune response against the drug) of ABBV-0805 following multiple ascending doses, administered every 28 days via intravenous (IV) …

  • 32 views
  • 23 Nov, 2020
  • 1 location
EC50 of Dexmedetomidine in Deep Brain Stimulation Implantation of Patients With Parkinson's Disease

Dexmedetomidine (DEX) sedation is widely used in deep brain stimulation implantation (DBSI) of patients With Parkinson's disease. However, intraoperative application of DEX may affect the discharge activity of deep brain nuclei and reduce the discharge frequency of Subthalamic nucleus (STN) neurons. At present, there is still a lack of prospective …

brain stimulation
  • 0 views
  • 27 Jun, 2022
  • 1 location
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela & C, S.A. It is approved as adjunctive therapy to preparations of L-DOPA/DDCI in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. Carbidopa and benserazide are both …

  • 0 views
  • 04 Aug, 2021
  • 1 location
The Effect of Repetitive Transcranial Magnetic Stimulation on the Cognition in People With Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disease. The cardinal symptoms of PD are tremor, rigidity, bradykinesia and postural instability. Cognitive impairment and dementia are also one of the key features of the non-motor symptoms of PD. At present, the mainstream treatment of PD-dementia is the dopaminergic rivastigmine. …

  • 0 views
  • 13 Apr, 2021
  • 1 location
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).

  • 0 views
  • 16 Jun, 2022
Clinical Trial for Near Infrared Endoventricular Illumination for Neuroprotection in Very Early Cases of Parkinson's Disease (Ev-NIRT) (Ev-NIRT)

Parkinson's disease has only pharmacological (essentially dopaminergic) and surgical treatment (essentially high-frequency deep brain stimulation), that are symptomatically effective. none of them is curative, and has the ability to slow down the disease and to protect dopaminergic neurons from death by neurodegeneration. Experimental results, based on preclinical studies, suggest that …

  • 0 views
  • 25 May, 2022
  • 1 location
Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder

Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading neurodegenerative disorders. Considering the fact that aged population is rapidly growing, it has become a critical issue to find more effective medications for these two disorders. The aim of this project is to examine the effectiveness and safety of …

  • 0 views
  • 05 Aug, 2021
  • 1 location
Repetitive Transcranial Magnetic Stimulation on Freezing of Gait in People With Parkinson's Disease

Parkinson's disease (PD) is the second most common neurodegenerative disease. The cardinal symptoms of PD are tremor, rigidity, bradykinesia and postural instability. Gait disturbance is also one of the key features of PD. At present, the mainstream treatment of PD is the dopaminergic supplement. However, the response to the medical …

  • 0 views
  • 11 Apr, 2021
  • 1 location
Trial of Parkinson's And Zoledronic Acid (TOPAZ)

with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome

Accepts healthy volunteers
screening procedures
progressive supranuclear palsy
atrophy
parkinson's disease
  • 256 views
  • 12 May, 2022
  • 53 locations